In Germany, approximately 30,000 treatments with radioiodine are performed yearly in patients with benign or malignant thyroid diseases.
These are carried out generally in specialized therapy wards which are equipped with radiation protection facilities.
Ambulant (fractionated) radioiodine treatment is not permitted in Germany, More recently, the situation has been that the discharge of patients is permitted, when they have spent a stay of at least 48 hours in the ward without the dose rate exceeding 3.5 muSv/hour at 2 meters distance from them, corresponding to 1 mSv/year (this correlates to a residual activity in the body of the patient of 250 MBq).
The radiation exposure of personnel in the therapy ward due to both external and internal exposure lies within a range of a few mSv per year According to recent studies, the exposure to family members and close friends via external exposure, inhalation or incorporation does not exceed the effective dose of 1 mSv/year, provided the patient has been treated at least for 48 h as an in-patient.
This value has been laid down in a recommendation by the European Union as the dose constraint for children ; for adults younger than 60 years of age, 3mSv are recommended, for older persons 15 mSv.
Mots-clés Pascal : Radiothérapie, Iode Isotope, Radioprotection, Recommandation, Législation, Europe, Malade, Personnel sanitaire, Exposition, Indication, Méthodologie, Thyroïde pathologie, Traitement, Interne, Médecine nucléaire, Endocrinopathie, Iode 131
Mots-clés Pascal anglais : Radiotherapy, Iodine Isotopes, Radioprotection, Recommendation, Legislation, Europe, Patient, Health staff, Exposure, Indication, Methodology, Thyroid diseases, Treatment, Internal, Nuclear medicine, Endocrinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0218626
Code Inist : 002B26M. Création : 16/11/1999.